Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Myriad Genetics (MYGN – Research Report), Revolution Medicines (RVMD – Research Report) and Demant (WILLF – Research Report).
Myriad Genetics (MYGN)
In a report released yesterday, Rachel Vatnsdal from J.P. Morgan maintained a Sell rating on Myriad Genetics, with a price target of $14.00. The company’s shares closed last Tuesday at $17.76.
According to TipRanks.com, Vatnsdal is a 1-star analyst with an average return of
Currently, the analyst consensus on Myriad Genetics is a Hold with an average price target of $19.25.
See today’s best-performing stocks on TipRanks >>
Revolution Medicines (RVMD)
J.P. Morgan analyst Eric Joseph maintained a Buy rating on Revolution Medicines yesterday and set a price target of $39.00. The company’s shares closed last Tuesday at $21.49.
According to TipRanks.com, Joseph is a 1-star analyst with an average return of
Revolution Medicines has an analyst consensus of Strong Buy, with a price target consensus of $35.00, representing a 64.0% upside. In a report issued on October 23, Needham also maintained a Buy rating on the stock with a $36.00 price target.
Demant (WILLF)
In a report released today, David Adlington from J.P. Morgan maintained a Buy rating on Demant, with a price target of DKK332.00. The company’s shares closed last Monday at $39.61.
According to TipRanks.com, Adlington has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Demant is a Moderate Buy with an average price target of $42.72, implying a 7.9% upside from current levels. In a report issued on October 24, Deutsche Bank also initiated coverage with a Buy rating on the stock with a DKK318.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MYGN:
- Myriad Genetics sees FY24 revenue $815M-$835M, consensus $799.97M
- Myriad Genetics narrows FY23 adjusted EPS view to (33c)-(28c) from (36c)-(24c)
- Myriad Genetics reports Q3 adjusted EPS (3c), consensus (8c)
- Myriad Genetics Reports Third Quarter 2023 Financial Results; Generates Double-Digit Revenue Growth; Raises 2023 Revenue Guidance and Introduces 2024 Revenue Guidance
- Myriad Genetics appoints Raha as Chief Operating Officer
